The new and completely redesigned website offers quick and easy access to essential and relevant information on SOM Biotech. This renewed design is aligned with the ambitious stage SOM Biotech is currently entering. After closing a successful €2M round and with its first large program out licensed (SOM0226 for TTR Amyloidosis), SOM Biotech is going through an exciting growth stage with the aim to be a global leader in the field of Repurposing Drugs for Orphan Diseases. Next $10M Series A are already opened to investors willing to participate in a uniquely capital/risk efficient business plan. www.sombiotech.com

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.